These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8339549)

  • 1. Monitoring of clinical trials: issues and recommendations.
    Fleming TR; DeMets DL
    Control Clin Trials; 1993 Jun; 14(3):183-97. PubMed ID: 8339549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Data monitoring and interim analyses in the pharmaceutical industry: ethical and logistical considerations.
    Rockhold FW; Enas GG
    Stat Med; 1993 Mar; 12(5-6):471-9. PubMed ID: 8493425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of external monitoring committees in clinical trials of the National Institute of Allergy and Infectious Diseases.
    Ellenberg SS; Myers MW; Blackwelder WC; Hoth DF
    Stat Med; 1993 Mar; 12(5-6):461-7; discussion 469. PubMed ID: 8493424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Data monitoring boards in the pharmaceutical industry.
    Herson J
    Stat Med; 1993 Mar; 12(5-6):555-61; discussion 563. PubMed ID: 8493431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Policies for study monitoring and interim reporting of results.
    Green SJ; Fleming TR; O'Fallon JR
    J Clin Oncol; 1987 Sep; 5(9):1477-84. PubMed ID: 3625262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials.
    DeMets DL; Fleming TR; Whitley RJ; Childress JF; Ellenberg SS; Foulkes M; Mayer KH; O'Fallon J; Pollard RB; Rahal JJ
    Control Clin Trials; 1995 Dec; 16(6):408-21. PubMed ID: 8720018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical issues in data monitoring of clinical trials: summary of responses to a questionnaire at NIH.
    Geller NL; Stylianou M
    Stat Med; 1993 Mar; 12(5-6):543-51; discussion 553. PubMed ID: 8493430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute.
    Smith MA; Ungerleider RS; Korn EL; Rubinstein L; Simon R
    J Clin Oncol; 1997 Jul; 15(7):2736-43. PubMed ID: 9215848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conflicts of interest in data monitoring of industry versus publicly financed clinical trials.
    Lachin JM
    Stat Med; 2004 May; 23(10):1519-21. PubMed ID: 15122730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Data monitoring committees and capturing relevant information of high quality.
    Fleming TR
    Stat Med; 1993 Mar; 12(5-6):565-70; discussion 571-3. PubMed ID: 8493432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring of clinical trials and interim analyses from a drug sponsor's point of view.
    Williams GW; Davis RL; Getson AJ; Gould AL; Hwang IK; Matthews H; Shih WJ; Snapinn SM; Walton-Bowen KL
    Stat Med; 1993 Mar; 12(5-6):481-92. PubMed ID: 8493426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Data monitoring committees for multicenter clinical trials sponsored by the National Institutes of Health. I. Roles and membership of data monitoring committees for trials sponsored by the National Eye Institute.
    Hawkins BS
    Control Clin Trials; 1991 Jun; 12(3):424-37. PubMed ID: 1651212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Data monitoring committees: the moral case for maximum feasible independence.
    Walters L
    Stat Med; 1993 Mar; 12(5-6):575-80; discussion 581-2. PubMed ID: 8493433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A survey of monitoring practices in cancer clinical trials.
    George SL
    Stat Med; 1993 Mar; 12(5-6):435-50. PubMed ID: 8493422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current issues surrounding women and minorities in drug trials.
    Wermeling DP; Selwitz AS
    Ann Pharmacother; 1993; 27(7-8):904-11. PubMed ID: 8364277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the independence of data monitoring committee in adaptive design clinical trials.
    Chow SC; Corey R; Lin M
    J Biopharm Stat; 2012; 22(4):853-67. PubMed ID: 22651119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early stopping, interim analyses, and monitoring committees: what are the tradeoffs?
    Zelen M
    J Clin Oncol; 1987 Sep; 5(9):1314-5. PubMed ID: 3625252
    [No Abstract]   [Full Text] [Related]  

  • 20. Some FDA perspectives on data monitoring in clinical trials in drug development.
    O'Neill RT
    Stat Med; 1993 Mar; 12(5-6):601-8; discussion 609-14. PubMed ID: 8493434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.